RxDoctor Payments Data

Kristina Kruse, MD

Family Medicine · Thomson, GANPI 1891288007

Payments from drug & device makers

$442in general payments, 2019–2025

Across 19 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$154
  • Pfizer$57
  • Bayer$41
  • AbbVie$41
  • Novo Nordisk$34
  • GSK$30
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$154
Pfizer3$57
Bayer2$41
AbbVie2$41
Novo Nordisk2$34
GSK2$30
Lilly USA, LLC1$20
Novartis1$18
Merck1$17
Amgen1$16
Mannkind Corporation1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$442 in reported general payments places this provider in the 45th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$222,535
Medicare patients
296
Services billed
6,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin203$286,144
EliquisApixaban153$194,829
OzempicSemaglutide95$155,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$99,091
FarxigaDapagliflozin Propanediol65$95,410
Breztri AerosphereBudesonide/Glycopyr/Formoterol92$89,930
TrulicityDulaglutide35$58,865
RybelsusSemaglutide21$57,661
Repatha SureclickEvolocumab48$48,545
MounjaroTirzepatide42$47,266
JanuviaSitagliptin Phosphate33$40,565
XareltoRivaroxaban27$34,124
SymbicortBudesonide/Formoterol Fumarate76$22,950
ArexvyRsvpref3 Antigen/As01e/Pf72$22,386
Breo ElliptaFluticasone/Vilanterol40$21,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$34$213,167116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$154$208,290233 claims
PfizerEliquis$57$194,829153 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$30$162,022299 claims
Lilly USA, LLCTrulicity, Mounjaro$20$106,13177 claims
MerckJanuvia$17$40,56533 claims
AbbVieLinzess$41$16,38812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Thomson

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →